Compare FKWL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | LSTA |
|---|---|---|
| Founded | 1981 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Misc Health and Biotechnology Services |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 28.9M |
| IPO Year | 1997 | 2000 |
| Metric | FKWL | LSTA |
|---|---|---|
| Price | $2.37 | $3.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $15.00 |
| AVG Volume (30 Days) | 28.2K | ★ 55.1K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,086,901.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 49.65 | ★ 56.90 |
| 52 Week Low | $2.31 | $1.81 |
| 52 Week High | $5.48 | $5.07 |
| Indicator | FKWL | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 38.66 |
| Support Level | N/A | $3.10 |
| Resistance Level | $3.79 | $3.41 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 25.64 | 5.48 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.